XEN Glaucoma Implant for the Management of Operated Uncontrolled Glaucoma: Results and Complications during a Long-Term Follow-Up

This study aimed to analyze the surgical and refractive outcomes of XEN glaucoma implant (Allergan, an Abbvie company, Irvine, CA, USA), a minimally invasive surgical device for the treatment of operated uncontrolled glaucoma. Eyes that received XEN Gel Stent placement from December 2014 to October...

Descripción completa

Detalles Bibliográficos
Autores principales: Lewczuk, Katarzyna, Konopińska, Joanna, Jabłońska, Joanna, Rudowicz, Jacek, Laszewicz, Patrycja, Mariak, Zofia, Rękas, Marek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8285170/
https://www.ncbi.nlm.nih.gov/pubmed/34306742
http://dx.doi.org/10.1155/2021/2321922

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8285170/
https://www.ncbi.nlm.nih.gov/pubmed/34306742
http://dx.doi.org/10.1155/2021/2321922

Ejemplares similares